Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-Month, Randomized, Open-Label, Phase IIA Study Evaluating the Safety and Efficacy of Siplizumab in Combination With Belatacept and MPA Compared to Standard of Care Immunosuppression in de Novo Renal Transplant Recipients (ASCEND)

NCT05669001 is registered in ClinicalTrials.gov with ITB-Med LLC as lead sponsor.

NCT NCT05669001
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05669001 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-Month, Randomized, Open-Label, Phase IIA Study Evaluating the Safety and Efficacy of Siplizumab in Combination With Belatacept and MPA Compared to Standard of Care Immunosuppression in de Novo Renal Transplant Recipients (ASCEND)
Lead sponsor
ITB-Med LLC
Phase
Phase 2
Overall status
Completed
Start date
December 28, 2023
Completion date
April 10, 2026
Enrollment
76 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

renal transplantation